On December 10, 2023, the launch conference of the new product launch of the live brucellosis vaccine (BA0711 strain) "Aobujing" hosted by Chongqing Aolong Biological Products***, a subsidiary of Huapai Biotechnology (Group) Co., Ltd., was held at the Yunnan Tengchong 2023 Veterinary Biological Products Forum!
At the meeting, Fu Gang, general manager of Chongqing Aolong Biological Products, gave a keynote speech entitled "Bubu for Win--- Bu Disease Vaccine (BA0711 Strain) "Ao Bujing". General Manager Fu Gang introduced the development history, business scope, operation management, talent strategy and other aspects of Aolong Biotechnology to the guests, and elaborated on the research and development, production process and characteristics of the product itself. He pointed out that there are still various shortcomings in animal brucellosis vaccines, and the ideal animal brucellosis vaccine needs to be effective, safe and identifiable in addition to being used in animals of different sexes and ages. Based on the current market demand, Aolong Biotech and China Agricultural University have joined forces, and after clinical trial verification in 4 provinces, 7 clinical bases and 9 test sites, the successful development of the brucellosis live vaccine (BA0711 strain) "Aobuzin" has six core advantages: human and animal safety, cattle and sheep universal, efficient protection, availability of pregnant animals, herd immunization, identification and purification. He emphasized that the "Aubjing" produced by Aolong Biotech is the first cloth disease vaccine that meets the ideal requirements of the World Health Organization (WHO), and won the "Brucellosis Vaccine Development Award" of the Global Animal Veterinary Alliance.